1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Context and Background
3.2. Overview of Oligonucleotide-based Products
3.3. Types of Oligonucleotides
3.3.1. Antisense Oligonucleotides
3.3.2. Aptamers
3.3.3. miRNA
3.3.4. shRNA
3.3.5. siRNA
3.3.6. Other Oligonucleotides
3.4. Custom Synthesis of Oligonucleotides
3.4.1. Process Development and Characterization
3.4.2. Analytical Method Development
3.4.3. Method Validation and Testing
3.4.4. Quality Control and Quality Assurance
3.4.5. Challenges Associated with Custom Synthesis of Oligonucleotides
3.5. Chemical Modification of Oligonucleotides
3.5.1. Backbone Modification
3.5.2. Sugar Ring Modification
3.6. Purification of Oligonucleotides
3.6.1. Desalting
3.6.2. Cartridge Purification
3.6.3. Polyacrylamide Gel Electrophoresis (PAGE)
3.6.4. High Performance Liquid Chromatography (HPLC)
3.7. Outsourcing Oligonucleotide Manufacturing
3.7.1. Need for Outsourcing
3.7.2. Commonly Outsourced Operations
3.7.3. Advantages of Outsourcing Manufacturing Operations
3.7.4. Guidelines for Selecting a Service Provider
3.8. Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
3.9. Recent Developments and Upcoming Trends

4. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
4.1. Chapter Overview
4.2. Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Application
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Geographical Location
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Regulatory Accreditations / Certifications
4.2.8. Analysis by Type of Oligonucleotide Manufactured
4.2.9. Analysis by Type of Offering
4.2.10. Analysis by Type of Manufacturing Service(s) Offered
4.2.11. Analysis by Type of Modification(s) Offered
4.2.12. Analysis by Type of Purification Method(s) Used
4.2.13. Analysis by Compliance to cGMP Standards

5. MARKET LANDSCAPE: OLIGONUCLEOTIDE MANUFACTURERES (THERAPEUTIC APPLICATIONS)
5.1. Chapter Overview
5.2. Oligonucleotide Manufacturers Focused on Therapeutic Applications: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Scale of Operation
5.2.4. Analysis by Geographical Location
5.2.5. Analysis by Location of Manufacturing Facilities
5.2.6. Analysis by Regulatory Accreditations / Certifications
5.2.7. Analysis by Type of Oligonucleotide Manufactured
5.2.8. Analysis by Type of Offering
5.2.9. Analysis by Type of Manufacturing Service(s) Offered
5.2.10. Analysis by Type of Modification(s) Offered
5.2.11. Analysis by Type of Purification Method(s) Used
5.2.12. Analysis by Compliance to cGMP Standards

6. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURES (RESEARCH AND DIAGNOSTIC APPLICATIONS)
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications
6.3.1. Oligonucleotide Manufacturers in North America
6.3.2. Oligonucleotide Manufacturers in Europe
6.3.3. Oligonucleotide Manufacturers in Asia-Pacific

7. COMPANY COMPETITIVENESS ANALYSIS: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
7.1. Chapter Overview
7.2. Key Assumptions and Methodology
7.3. Company Competitiveness Analysis: Oligonucleotide Manufacturers Focused on Therapeutic Applications
7.3.1. Oligonucleotide Manufacturers in North America
7.3.2. Oligonucleotide Manufacturers in Europe
7.3.3. Oligonucleotide Manufacturers in Asia-Pacific

8. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (RESEARCH AND DIAGNOSTIC APPLICATIONS)
8.1. Chapter Overview
8.2. Ajinomoto Bio-Pharma Services
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Manufacturing Facilities and Capabilities
8.2.4. Recent Developments and Future Outlook
8.3. Integrated DNA Technologies
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Manufacturing Facilities and Capabilities
8.3.4. Recent Developments and Future Outlook
8.4. Kaneka Eurogentec
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Manufacturing Facilities and Capabilities
8.4.4. Recent Developments and Future Outlook
8.5. LGC Biosearch Technologies
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Manufacturing Facilities and Capabilities
8.5.4. Recent Developments and Future Outlook
8.6. Microsynth
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Manufacturing Facilities and Capabilities
8.6.4. Recent Developments and Future Outlook
8.7. Sigma Aldrich
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Service Portfolio
8.7.4. Manufacturing Facilities and Capabilities
8.7.5. Recent Developments and Future Outlook
8.8. Thermo Fisher Scientific
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Service Portfolio
8.8.4. Manufacturing Facilities and Capabilities
8.8.5. Recent Developments and Future Outlook

9. COMPANY PROFILES: OLIGONUCLEOTIDE MANUFACTURERS (THERAPEUTIC APPLICATIONS)
9.1. Chapter Overview
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities
9.2.5. Recent Developments and Future Outlook
9.3. BioSpring
9.3.1. Company Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities
9.3.4. Recent Developments and Future Outlook
9.4. CordenPharma
9.4.1. Company Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities
9.4.4. Recent Developments and Future Outlook
9.5. Nitto Denko Avecia
9.5.1. Company Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities
9.5.4. Recent Developments and Future Outlook
9.6. TriLink Biotechnologies
9.6.1. Company Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities
9.6.4. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Oligonucleotide Manufacturers: Recent Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Most Active Players: Analysis by Number of Partnerships
10.3.5. Geographical Analysis
10.3.5.1. Most Active Players: Geographical Distribution by Number of Partnerships
10.3.5.2. Intercontinental and Intracontinental Agreements

11. RECENT EXPANSIONS
11.1. Chapter Overview
11.2. Oligonucleotide Manufacturers: Recent Expansions
11.2.1. Analysis by Year of Expansion
11.2.2. Analysis by Type of Expansion
11.2.3. Analysis by Application
11.2.4. Analysis by Location of Facility
11.2.5. Analysis by Expanded Facility Area
11.2.6. Analysis by Expanded Scale of Operation
11.3.7. Most Active Players: Analysis by Number of Expansions
11.3.8. Geographical Analysis
11.3.8.1. Continent-wise Distribution
11.3.8.2. Country-wise Distribution

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Clinical Trial Analysis: Oligonucleotide-based Drug Products
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis by Phase of Development
12.3.3. Analysis by Type of Oligonucleotide
12.3.4. Analysis by Trial Recruitment Status
12.3.5. Analysis by Trial Focus Area
12.3.6. Analysis by Target Therapeutic Area
12.3.7. Geographical Analysis by Number of Clinical Trials
12.3.8. Geographical Analysis by Enrolled Patient Population
12.3.9. Analysis by Type of Sponsor / Collaborator
12.3.10. Most Active Players: Analysis by Number of Registered Trials
12.3.11. Competitive Benchmarking (Clinical Research): Active Industry Players

13. CAPACITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Oligonucleotide Manufacturers: Global, Installed Capacity
13.3.1. Analysis by Company Size
13.3.2. Analysis by Scale of Operation
13.3.3. Analysis by Location of Manufacturing Facility
13.4. Concluding Remarks

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Commercial Demand for Oligonucleotide Manufacturing
14.3.1. Analysis by Target Therapeutic Area
14.3.2. Analysis by Scale of Operation
14.3.3. Analysis by Geography
14.4. Global Clinical Demand for Oligonucleotide Manufacturing
14.4.1. Analysis by Target Therapeutic Area
14.4.2. Analysis by Scale of Operation
14.4.3. Analysis by Geography
14.5. Demand and Supply Analysis
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Forecast Methodology
15.3. Overall Oligonucleotide Manufacturing Market, 2020-2030
15.4. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Application
15.4.1. Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030
15.4.2. Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030
15.5. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Type of Oligonucleotide Manufactured
15.5.1. Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030
15.5.2. Oligonucleotide Manufacturing Market for siRNA, 2020-2030
15.5.3. Oligonucleotide Manufacturing Market for miRNA, 2020-2030
15.5.4. Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030
15.6. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Scale of Operation
15.6.1. Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030
15.6.2. Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030
15.7. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Company Size
15.7.1. Oligonucleotide Manufacturing Market for Small Companies, 2020-2030
15.7.2. Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030
15.7.3. Oligonucleotide Manufacturing Market for Large Companies, 2020-2030
15.8. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Target Therapeutic Area
15.8.1. Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030
15.8.2. Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030
15.8.3. Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030
15.8.4. Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030
15.8.5. Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030
15.9. Oligonucleotide Manufacturing Market, 2020-2030: Analysis by Geography
15.9.1. Oligonucleotide Manufacturing Market in North America, 2020-2030
15.9.2. Oligonucleotide Manufacturing Market in Europe, 2020-2030
15.9.3. Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030
15.9.4. Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors

17. SURVEY ANALYSIS
17.1. Chapter Overview
17.2. Overview of Respondents
17.2.1. Seniority Level of Respondents
17.3. Survey Insights
17.3.1. Type of Offering
17.3.2. Application
17.3.3. Manufacturing Capacity
17.3.4. Location of Manufacturing Facilities
17.3.5. Extent of Outsourcing
17.3.6. Current Market Opportunity

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. BianoScience
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Tobias Pohlmann, Founder and Managing Director
18.3. IBA Life Sciences
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Joachim Bertram, Chief Scientific Officer and Managing Director

19. CONCLUDING REMARKS
19.1. Chapter Overview
19.2. Key Takeaways

20. APPENDIX 1: TABULATED DATA

21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Classification of Oligonucleotides
Figure 3.2 Steps Involved in the Manufacturing of Oligonucleotides
Figure 3.3 Types of Chemical Modifications of Oligonucleotides
Figure 3.4 Types of Purification Methods Used for Oligonucleotides
Figure 3.5 Types of Standalone Service Providers
Figure 3.6 Services Offered by Oligonucleotide Manufacturers
Figure 3.7 Commonly Outsourced Operations
Figure 3.8 Guidelines for Selecting a Service Provider
Figure 3.9 Growth Drivers and Roadblocks to Oligonucleotide Manufacturing
Figure 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Figure 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Figure 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
Figure 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Figure 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
Figure 4.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 4.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
Figure 4.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 4.9 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.10 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 4.11 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 4.12 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Offering
Figure 4.13 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 4.14 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Modification(s) Offered
Figure 4.15 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Type of Purification Method(s) Used
Figure 4.16 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Compliance to cGMP Standards
Figure 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment
Figure 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Company Size
Figure 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Scale of Operation
Figure 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Year of Establishment, Company Size and Scale of Operation
Figure 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Region-wise)
Figure 5.6 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Headquarters (Country-wise)
Figure 5.7 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 5.8 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 5.9 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Regulatory Accreditations / Certifications
Figure 5.10 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Oligonucleotide Manufactured
Figure 5.11 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Offering
Figure 5.12 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Manufacturing Service(s) Offered
Figure 5.13 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Modification(s) Offered
Figure 5.14 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Type of Purification Method(s) Used
Figure 5.15 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Distribution by Compliance to cGMP Standards
Figure 6.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in North America
Figure 6.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Europe
Figure 6.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications in Asia-Pacific
Figure 7.1 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in North America
Figure 7.2 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Europe
Figure 7.3 Competitiveness Analysis of Oligonucleotide Manufacturers Focused on Therapeutic Applications in Asia-Pacific
Figure 8.1 Sigma Aldrich: Net Revenues, FY 2015 - H1 FY 2019 (USD Million)
Figure 8.2 Sigma Aldrich: Distribution of Net Revenues by Business Segment, FY 2018 (USD Million)
Figure 8.3 Thermo Fisher Scientific: Net Revenues, FY 2014 - FY 2019 (USD Billion)
Figure 8.4 Thermo Fisher Scientific: Distribution of Net Revenues by Business Segment, FY 2019 (USD Billion)
Figure 9.1 Agilent Technologies: Net Revenues, FY 2015 - FY 2018 (USD Billion)
Figure 9.2 Agilent Technologies: Distribution of Net Revenues by Business Segment, FY 2018 (USD Billion)
Figure 10.1 Partnerships and Collaborations: Distribution by Year of Partnership, 2014-2019
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2014-2019
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Most Active Players: Geographical Distribution by Number of Partnerships
Figure 10.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Recent Expansions: Distribution by Year of Expansion, 2014-2019
Figure 11.2 Recent Expansions: Distribution by Type of Expansion
Figure 11.3 Recent Expansions: Year-wise Trend by Type of Expansion, 2014-2019
Figure 11.4 Recent Expansions: Distribution by Application
Figure 11.5 Recent Expansions: Distribution by Location of Facility
Figure 11.6 Recent Expansions: Distribution by Type of Expansion and Location of Facility
Figure 11.7 Recent Expansions: Distribution by Type of Expansion and Application
Figure 11.8 Recent Expansions: Distribution by Expanded Facility Area (sq ft)
Figure 11.9 Recent Expansions: Distribution by Expanded Scale of Operation
Figure 11.10 Most Active Players: Distribution by Number of Expansions
Figure 11.11 Recent Expansions: Distribution by Geography
Figure 11.12 Recent Expansions: Year-wise Trend by Geography, 2014-2019
Figure 12.1 Clinical Trials: Distribution by Trial Registration Year, Pre-2012-2019
Figure 12.2 Clinical Trials: Distribution by Phase of Development
Figure 12.3 Clinical Trials: Distribution by Type of Oligonucleotide
Figure 12.4 Clinical Trials: Distribution by Trial Registration Year and Type of Oligonucleotide, Pre-2012-2019
Figure 12.5 Clinical Trials: Distribution by Trial Recruitment Status
Figure 12.6 Clinical Trials: Distribution by Trial Registration Year and Recruitment Status, Pre-2012-2019
Figure 12.7 Clinical Trials: Popular Keywords
Figure 12.8 Clinical Trials: Distribution by Target Therapeutic Area
Figure 12.9 Clinical Trials: Distribution by Trial Registration Year and Target Therapeutic Area, Pre-2012-2019
Figure 12.10 Clinical Trials: Geographical Distribution by Number of Clinical Trials
Figure 12.11 Clinical Trials: Geographical Distribution by Trial Registration Year, Pre-2012-2019
Figure 12.12 Clinical Trials: Geographical Distribution by Enrolled Patient Population
Figure 12.13 Clinical Trials: Cumulative Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2012-2019
Figure 12.14 Clinical Trials: Distribution by Type of Sponsor / Collaborator
Figure 12.15 Clinical Trials: Distribution by Type of Sponsor / Collaborator and Target Therapeutic Area
Figure 12.16 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 12.17 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.18 Clinical Trials: Distribution by Trial Registration Year and Most Active Industry Players, 2014-2019
Figure 12.19 Clinical Trials: Benchmarking by Number of Trials across Key Therapeutic Areas
Figure 13.1 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Sample Data Set)
Figure 13.2 Global Oligonucleotide Manufacturing Capacity: Distribution by Company Size (Grams)
Figure 13.3 Global Oligonucleotide Manufacturing Capacity: Distribution by Scale of Operation (Grams)
Figure 13.4 Global Oligonucleotide Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Grams)
Figure 14.1 Global, Commercial Demand for Oligonucleotide Manufacturing (Grams)
Figure 14.2 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Figure 14.3 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Figure 14.4 Global, Commercial Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Figure 14.5 Global, Clinical Demand for Oligonucleotide Manufacturing (Grams)
Figure 14.6 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Target Therapeutic Area (Grams)
Figure 14.7 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Scale of Operation (Grams)
Figure 14.8 Global, Clinical Demand for Oligonucleotide Manufacturing: Distribution by Geography (Grams)
Figure 14.8 Global Oligonucleotide Manufacturing: Demand and Supply
Figure 15.1 Overall Oligonucleotide Manufacturing Market, 2020-2030 (USD Million)
Figure 15.2 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Application (USD Million)
Figure 15.3 Oligonucleotide Manufacturing Market Focused on Research and Diagnostic Applications, 2020-2030 (USD Million)
Figure 15.4 Oligonucleotide Manufacturing Market Focused on Therapeutic Applications, 2020-2030 (USD Million)
Figure 15.5 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Type of Oligonucleotide Manufactured (USD Million)
Figure 15.6 Oligonucleotide Manufacturing Market for Antisense Oligonucleotides, 2020-2030 (USD Million)
Figure 15.7 Oligonucleotide Manufacturing Market for siRNA, 2020-2030 (USD Million)
Figure 15.8 Oligonucleotide Manufacturing Market for miRNA, 2020-2030 (USD Million)
Figure 15.9 Oligonucleotide Manufacturing Market for Other Oligonucleotides, 2020-2030 (USD Million)
Figure 15.10 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 15.11 Oligonucleotide Manufacturing Market for Preclinical / Clinical Scale Operations, 2020-2030 (USD Million)
Figure 15.12 Oligonucleotide Manufacturing Market for Commercial Scale Operations, 2020-2030 (USD Million)
Figure 15.13 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Company Size (USD Million)
Figure 15.14 Oligonucleotide Manufacturing Market for Small Companies, 2020-2030 (USD Million)
Figure 15.15 Oligonucleotide Manufacturing Market for Mid-sized Companies, 2020-2030 (USD Million)
Figure 15.16 Oligonucleotide Manufacturing Market for Large Companies, 2020-2030 (USD Million)
Figure 15.17 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Million)
Figure 15.18 Oligonucleotide Manufacturing Market for Oncological Disorders, 2020-2030 (USD Million)
Figure 15.19 Oligonucleotide Manufacturing Market for Eye Disorders, 2020-2030 (USD Million)
Figure 15.20 Oligonucleotide Manufacturing Market for Metabolic Disorders, 2020-2030 (USD Million)
Figure 15.21 Oligonucleotide Manufacturing Market for Autoimmune Disorders, 2020-2030 (USD Million)
Figure 15.22 Oligonucleotide Manufacturing Market for Other Therapeutic Areas, 2020-2030 (USD Million)
Figure 15.23 Oligonucleotide Manufacturing Market, 2020-2030: Distribution by Geography (USD Million)
Figure 15.24 Oligonucleotide Manufacturing Market in North America, 2020-2030 (USD Million)
Figure 15.25 Oligonucleotide Manufacturing Market in Europe, 2020-2030 (USD Million)
Figure 15.26 Oligonucleotide Manufacturing Market in Asia-Pacific, 2020-2030 (USD Million)
Figure 15.27 Oligonucleotide Manufacturing Market in Rest of the World, 2020-2030 (USD Million)
Figure 16.1 Oligonucleotide Manufacturing Market: SWOT Analysis
Figure 16.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 17.1 Survey Insights: Distribution by Type of Organization
Figure 17.2 Survey Insights: Distribution by Location of Organization
Figure 17.3 Survey Insights: Distribution by Seniority Level
Figure 17.4 Survey Insights: Distribution by Type of Offering
Figure 17.5 Survey Insights: Distribution by Application
Figure 17.6 Survey Insights: Distribution by Location of Manufacturing Facilities
Figure 17.7 Survey Insights: Distribution by Extent of Outsourcing
Figure 17.8 Survey Insights: Distribution by Current Market Opportunity

List of Tables
Table 4.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: List of Industry Players
Table 4.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 4.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 4.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Manufacturing Service(s) Offered
Table 4.5 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
Table 5.1 Oligonucleotide Manufacturers Focused on Therapeutic Applications: List of Industry Players
Table 5.2 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Location of Manufacturing Facilities and Regulatory Accreditations / Certifications
Table 5.3 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Oligonucleotide Manufactured and Type of Offering
Table 5.4 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Manufacturing Service(s) Offered
Table 5.5 Oligonucleotide Manufacturers Focused on Therapeutic Applications: Information on Type of Modification(s) Offered, Type of Purification Method(s) Used and Compliance to cGMP Standards
Table 8.1 Ajinomoto Bio-Pharma Services: Key Highlights
Table 8.2 Ajinomoto Bio-Pharma Services: Service Portfolio
Table 8.3 Ajinomoto Bio-Pharma Services: Manufacturing Facilities and Capabilities
Table 8.4 Ajinomoto Bio-Pharma Services: Recent Developments and Future Outlook
Table 8.5 Integrated DNA Technologies: Key Highlights
Table 8.6 Integrated DNA Technologies: Service Portfolio
Table 8.7 Integrated DNA Technologies: Manufacturing Facilities and Capabilities
Table 8.8 Integrated DNA Technologies: Recent Developments and Future Outlook
Table 8.9 Kaneka Eurogentec: Key Highlights
Table 8.10 Kaneka Eurogentec: Service Portfolio
Table 8.11 Kaneka Eurogentec: Manufacturing Facilities and Capabilities
Table 8.12 Kaneka Eurogentec: Recent Developments and Future Outlook
Table 8.13 LGC, Biosearch Technologies: Key Highlights
Table 8.14 LGC, Biosearch Technologies: Service Portfolio
Table 8.15 LGC, Biosearch Technologies: Manufacturing Facilities and Capabilities
Table 8.16 LGC, Biosearch Technologies: Recent Developments and Future Outlook
Table 8.17 Microsynth: Key Highlights
Table 8.18 Microsynth: Service Portfolio
Table 8.19 Microsynth: Manufacturing Facilities and Capabilities
Table 8.20 Microsynth: Recent Developments and Future Outlook
Table 8.21 Sigma Aldrich: Key Highlights
Table 8.22 Sigma Aldrich: Service Portfolio
Table 8.23 Sigma Aldrich: Manufacturing Facilities and Capabilities
Table 8.24 Sigma Aldrich: Recent Developments and Future Outlook
Table 8.25 Thermo Fisher Scientific: Key Highlights
Table 8.26 Thermo Fisher Scientific: Service Portfolio
Table 8.27 Thermo Fisher Scientific: Manufacturing Facilities and Capabilities
Table 8.28 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 9.1 Agilent Technologies: Key Highlights
Table 9.2 Agilent Technologies: Service Portfolio
Table 9.3 Agilent Technologies: Manufacturing Facilities and Capabilities
Table 9.4 Agilent Technologies: Recent Developments and Future Outlook
Table 9.5 BioSpring: Key Highlights
Table 9.6 BioSpring: Service Portfolio
Table 9.7 BioSpring: Manufacturing Facilities and Capabilities
Table 9.8 BioSpring: Recent Developments and Future Outlook
Table 9.9 CordenPharma: Key Highlights
Table 9.10 CordenPharma: Service Portfolio
Table 9.11 CordenPharma: Manufacturing Facilities and Capabilities
Table 9.12 CordenPharma: Recent Developments and Future Outlook
Table 9.13 Nitto Denko Avecia: Key Highlights
Table 9.14 Nitto Denko Avecia: Service Portfolio
Table 9.15 Nitto Denko Avecia: Manufacturing Facilities and Capabilities
Table 9.16 Nitto Denko Avecia: Recent Developments and Future Outlook
Table 9.17 TriLink Biotechnologies: Key Highlights
Table 9.18 TriLink Biotechnologies: Service Portfolio
Table 9.19 TriLink Biotechnologies: Manufacturing Facilities and Capabilities
Table 9.20 TriLink Biotechnologies: Recent Developments and Future Outlook
Table 10.1 Oligonucleotide Manufacturers: List of Partnerships, 2014-2019
Table 10.2 Most Active Players: Geographical Distribution by Type of Partnership Model
Table 11.1 Oligonucleotide Manufacturers: List of Expansions, 2014-2019
Table 13.1 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Company Size (Sample Data Set)
Table 13.2 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Scale of Operation (Sample Data Set)
Table 13.3 Global Oligonucleotide Manufacturing Capacity: Average Capacity based on Location of Company (Sample Data Set)
Table 17.1 Survey Insights: Overview of Respondents
Table 17.2 Survey Insights: Seniority Level of Respondents
Table 17.3 Survey Insights: Type of Offering
Table 17.4 Survey Insights: Application
Table 17.5 Survey Insights: Oligonucleotide Manufacturing Capacity
Table 17.6 Survey Insights: Number and Location of Manufacturing Facilities
Table 17.7 Survey Insights: Extent of Outsourcing
Table 17.8 Survey Insights: Current Market Opportunity (USD Million)
Table 18.1 BianoScience: Key Highlights
Table 18.2 IBA Life Sciences: Key Highlights
Table 19.1 Oligonucleotide Manufacturing Market: Key Takeaways
Table 20.1 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Year of Establishment
Table 20.2 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Company Size
Table 20.3 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Application
Table 20.4 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Scale of Operation
Table 20.6 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Region-wise)
Table 20.7 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Headquarters (Country-wise)
Table 20.8 Oligonucleotide Manufacturers Focused on Research and Diagnostic Applications: Distribution by Location of Manufacturing Facilities (Region-wise)

Please contact our Customer Support Center to get the complete Table of Contents